Journal article
Nonribosomal Assembly of Natural Lipocyclocarbamate Lipoprotein‐Associated Phospholipase Inhibitors
Abstract
EXPANDING OUR KNOWLEDGE: Natural lipocyclocarbamate natural products have provided the inspiration for the first-in-class synthetic phospholipase inhibitor darapladib, currently in phase III clinical trials for the treatment of atherosclerosis. Here, we discuss their biosynthesis by a nonribosomal peptide synthetase.
Authors
Johnston CW; Zvanych R; Khyzha N; Magarvey NA
Journal
ChemBioChem, Vol. 14, No. 4, pp. 431–435
Publisher
Wiley
Publication Date
March 4, 2013
DOI
10.1002/cbic.201200598
ISSN
1439-4227